Annual Report of Activities CNC 2008 - Center for Neuroscience and ...

The effect of Ruboxistaurin on clinically significant Macular Edema in patients with diabetes Mellitus, asassessed by optical coherence tomographyA randomized, double‐masked, parallel group, multi‐center, dose‐finding comparison of the safety and efficacyof ASI‐001A 0.5 μg/day and ASI‐001B 0.2 μg/day fluocinolone acetonide intravitreal inserts to sham injection insubjects with diabetic macular edemaA 3‐Year, Phase 3, Multicenter, Masked, Randomized, Sham‐Controlled Trial to Assess the Safety and Efficacy of700 μg and 350μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System inthe Treatment of Patients with Diabetic Macular EdemaA Phase 2/3 Randomized, Controlled, Double‐Masked, Multi‐Center, Comparative Dose‐Finding Trial, in ParallelGroups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.003mg Pagaptanib Sodium(Macugen®), Given as Often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic MacularEdema (DME) involving the Center of the MaculaGlaucomaA five‐year, multicenter, open‐label study to evaluate the safety of once‐daily evening instillation of travoprost0,004% eyedrops (Travatan®) in subjects with open‐angle glaucoma or ocular hypertensionStudy of the Efficacy and Safety of Travatan® Therapy compared with Cosopt® Therapy in Patients with Open‐Angle Glaucoma or Ocular HypertensionA phase 1, Open‐Label study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult GlaucomaPatients Treated with Latanoprost 0,005%A phase 3 Prospective, Randomized, Double‐Masked, 12‐week, parallel group Study evaluating the efficacy andsafety of Latanoprost and Timolol in Pediatric subjects with Glaucoma135Age‐Related Macular DegenerationA 102‐week, open label, multicenter trial to investigate the efficacy of macugen for the preservation of visualfunction in subjects with neovascular age‐related macular degeneration (AMD) and to assess the benefit oftreating early choroidal neovascularization (CNV)A phase 3, randomized, double‐masked, parallel‐assignment study of intravitreal bevasiranib sodium,administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared withLucentis® monotherapy every 4 weeks in patients with Exsudative Age‐Related Macular Degeneration (AMD)A phase IV, long‐term, open‐label, multicenter extension study to evaluate the safety and tolerability ofranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age‐related maculardegeneration (AMD)Early Markers of choroidal neovascularization (CNV) in fellow eyes of patients with Age‐Related MacularDegeneration (AMD) and CNV in one eyeA 6‐Month, Single‐Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of700μg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy toLucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal NeovascularizationSecondary to Age‐Related Macular DegenerationA randomized, double‐masked, active controlled, phase 3 study of the efficacy, safety, and tolerability ofrepeated doses of intravitreal VEGF Trop‐Eye in subjects with neovascular age‐relatedCataractA Multicenter, Investigator‐Masked, Parallel‐Group, Randomized, Study of the Efficacy and Safety ofIndomethacin 0,1% Eyedrops Compared with Kerorolac 0,5% Eyedrops in Ocular Inflammation After CataractSurgery